Familial medullary thyroid carcinoma: Clinical variability and low aggressiveness associated with RET mutation at codon 804

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 4, 2002, Pages 1674-1680

  Lombardo, Francesca ^a   Baudin, Eric ^a,b   Chiefari, Eusebio ^a,b,c   Arturi, Franco ^a,b,c,d   Bardet, Stephane ^a,b,c,d,e   Caillou, Bernard ^a,b,c,d   Conte, Chiara ^a,b,c,d,e,f   Dallapiccola, Bruno ^a,b,c,f,g   Giuffrida, Dario ^a,b,c,f,g   Bidart, Jean Michel ^a,b,f,g   Schlumberger, Martin ^a,b,g   Filetti, Sebastiano ^{a,b,c,d,e,f,g}  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e SAN LUIGI GONZAGA HOSPITAL   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g POLICLINICO UMBERTO I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; PENTAGASTRIN; PROTEIN RET;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CODON; DIAGNOSTIC TEST; FAMILIAL CANCER; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PEDIGREE; PRIORITY JOURNAL; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY;

EID: 18444380535     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.4.8403     Document Type: Article

References (28)

1. The relationship between specific RET proto-oncogene mutation and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium Analysis
2. RET proto-oncogene in the development of human cancer
3. The RET proto-oncogene in human cancers
4. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A
5. Early or prophylactic thyroidectomy in MEN2/FMTC gene carriers: Results in 71 thyroidectomized patients
6. Familial medullary thyroid carcinoma with noncysteine RET mutations: Phenotype-genotype relationship in a large series of patients
7. Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity
8. RET mutations in exons 13 and 14 of FMTC patients
9. Oncogenic activation of RET by two distinct FMTC mutation affecting the tyrosine kinase domain
10. Familial medullary thyroid carcinoma: Presymptomatic diagnosis and management in children
11. A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto oncogene in two families affected by familial medullary thyroid carcinoma
12. Update on the MEN 2A c804 RET mutation: Is prophylactic thyroidectomy indicated?
13. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG→ATG) mutation
14. Construction and clinical validation of a sensitive and specific assay for mature calcitonin using monoclonal anti-peptide antibodies
15. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: Comparison with genetic screening in hereditary medullary thyroid carcinoma
16. Cloning and expression of the RET proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains
17. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma
18. A large family with hereditary MTC: Role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC
19. A case of metastatic medullary thyroid carcinoma: Early identification before surgery of a RET proto-oncogene somatic mutation in fine needle aspirate specimen
20. Age related probability of development of hereditary medullary thyroid carcinoma
21. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A. An 18-year experience
22. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A
23. Risk estimation and screening in families of patients with medullary thyroid carcinoma
24. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: Results in 899 patients
25. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation
26. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma
27. Heterogeneous mutations of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma
28. A RET double mutation in the germline of a kindred with FMTC